Obstructive sleep apnea technology developer Vivos Therapeutics has entered into a securities private purchase agreement, which is expected to gross the company about $4 million.
The deal, which is expected to close on November 2, involves the purchase and sale of approximately 980,000 shares of Vivos’ common stock at a purchase price of $4.08 per share. Vivos intends to use the net proceeds from the offering for general corporate purposes.
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
